{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:55:42Z","timestamp":1791053742071,"version":"4.1.0"},"reference-count":163,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Fibroblast growth factor 23 (FGF23) was identified at the turn of the century as the long-sought circulating phosphatonin in human pathology. Since then, several clinical and experimental studies have investigated the metabolism of FGF23 and revealed its relevant pathogenic role in various diseases. Most of these studies have been performed in adult individuals. However, the mineral metabolism of the child is, to a large extent, different from that of the adult because, in addition to bone remodeling, the child undergoes a specific process of endochondral ossification responsible for adequate mineralization of long bones\u2019 metaphysis and growth in height. Vitamin D metabolism is known to be deeply involved in these processes. FGF23 might have an influence on bones\u2019 growth as well as on the high and age-dependent serum phosphate concentrations found in infancy and childhood. However, the interaction between FGF23 and vitamin D in children is largely unknown. Thus, this review focuses on the following aspects of FGF23 metabolism in the pediatric age: circulating concentrations\u2019 reference values, as well as those of other major variables involved in mineral homeostasis, and the relationship with vitamin D metabolism in the neonatal period, in vitamin D deficiency, in chronic kidney disease (CKD) and in hypophosphatemic disorders.<\/jats:p>","DOI":"10.3390\/ijms24076661","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T03:32:59Z","timestamp":1680492779000},"page":"6661","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Mineral Metabolism in Children: Interrelation between Vitamin D and FGF23"],"prefix":"10.3390","volume":"24","author":[{"given":"Oscar D.","family":"Pons-Belda","sequence":"first","affiliation":[{"name":"Hospital Can Misses, 07800 Ibiza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-3346","authenticated-orcid":false,"given":"M\u00aa Agustina","family":"Alonso-\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Central de Asturias, 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan David","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Santa Luc\u00eda, 30202 Cartagena, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6770-8263","authenticated-orcid":false,"given":"Laura","family":"Mantec\u00f3n-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Central de Asturias, 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Santos-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Central de Asturias, 33011 Oviedo, Spain"},{"name":"Department of Medicine, Faculty of Medicine, University of Oviedo, 33003 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11154-015-9318-z","article-title":"The PTH-Vitamin D-FGF23 axis","volume":"16","author":"Blau","year":"2015","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1689S","DOI":"10.1093\/ajcn\/80.6.1689S","article-title":"Overview of general physiologic features and functions of vitamin D","volume":"80","author":"DeLuca","year":"2004","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/archdischild-2012-302585","article-title":"Vitamin D and child health: Part 2 (extraskeletal and other aspects)","volume":"98","author":"Shaw","year":"2013","journal-title":"Arch. Dis. Child."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1006\/bbrc.2000.3696","article-title":"Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain","volume":"277","author":"Yamashita","year":"2000","journal-title":"Biochem. Biophys. Res. Commum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.bone.2004.06.014","article-title":"Bone as a source of FGF23: Regulation by phosphate?","volume":"35","author":"Mirams","year":"2004","journal-title":"Bone"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature25451","article-title":"\u03b1-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling","volume":"553","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"E310-20","DOI":"10.1152\/ajpendo.00460.2012","article-title":"Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo","volume":"304","author":"Quinn","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature"},{"key":"ref_9","unstructured":"Horowitz, G.L., Altaie, S., and Boyd, J.C. (2008). CLSI C28-A3: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory, CLSI. [3rd ed.]."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1515\/CCLM.2004.120","article-title":"Selecting clinically relevant populations for reference intervals","volume":"42","author":"Ritchie","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.clinbiochem.2005.11.015","article-title":"Pediatric reference intervals for bone markers","volume":"39","author":"Yang","year":"2006","journal-title":"Clin. Biochem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1258\/acb.2012.011274","article-title":"Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase","volume":"49","author":"Fischer","year":"2012","journal-title":"Ann. Clin. Biochem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1373\/clinchem.2011.177741","article-title":"Closing the gaps in pediatric laboratory reference intervals: A CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children","volume":"58","author":"Colantonio","year":"2012","journal-title":"Clin. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cca.2018.12.011","article-title":"Pediatric reference intervals for clinical chemistry assays on Siemens ADVIA XPT\/1800 and Dimension EXL in the CALIPER cohort of healthy children and adolescents","volume":"490","author":"Tahmasebi","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1515\/cclm-2017-0767","article-title":"Pediatric reference intervals for 1,25-dihydroxyvitamin D using the DiaSorin LIAISON XL assay in the healthy CALIPER cohort","volume":"56","author":"Higgins","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1373\/clinchem.2013.204222","article-title":"Marked biological variance in endocrine and biochemical markers in childhood: Establishment of pediatric reference intervals using healthy community children from the CALIPER cohort","volume":"59","author":"Bailey","year":"2013","journal-title":"Clin. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1515\/cclm-2015-0558","article-title":"Pediatric reference value distributions and covariate-stratified reference intervals for 29 endocrine and special chemistry biomarkers on the Beckman Coulter Immunoassay Systems: A CALIPER study of healthy community children","volume":"54","author":"Karbasy","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1515\/cclm-2020-0041","article-title":"Corrigendum to: Pediatric reference intervals for 29 Ortho VITROS 5600 immunoassays using the CALIPER cohort of healthy children and adolescents","volume":"58","author":"Higgins","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1515\/cclm-2019-0707","article-title":"Paediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents","volume":"57","author":"Bohn","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bone.2014.05.012","article-title":"Fibroblast growth factor 23 and Klotho serum levels in healthy children","volume":"66","author":"Gkentzi","year":"2014","journal-title":"Bone"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s00774-020-01173-3","article-title":"Incidence rate of vitamin D deficiency and FGF23 levels in 12- to 13-year-old adolescents in Japan","volume":"39","author":"Koyama","year":"2021","journal-title":"J. Bone Miner. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1018523","DOI":"10.3389\/fendo.2022.1018523","article-title":"Determination of iFGF23 upper reference limits (URL) in healthy pediatric population, for its better correct use","volume":"13","author":"Brescia","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1210\/endo.138.9.5398","article-title":"24R,25-dihydroxyvitamin D3: An essential vitamin D3 metabolite for both normal bone integrity and healing of tibial fracture in chicks","volume":"138","author":"Seo","year":"1997","journal-title":"Endocrinology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101062","DOI":"10.1016\/j.siny.2019.101062","article-title":"Calciotropic and phosphotropic hormones in fetal and neonatal bone development","volume":"25","author":"Ryan","year":"2020","journal-title":"Semin. Fetal Neonatal Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1152\/physrev.00014.2014","article-title":"Bone development and mineral homeostasis in the fetus and neonate: Roles of the calciotropic and phosphotropic hormones","volume":"94","author":"Kovacs","year":"2014","journal-title":"Physiol. Rev."},{"key":"ref_26","first-page":"252","article-title":"FGF23 is not required to regulate fetal phosphorus metabolism but exerts effects within 12 hours after birth","volume":"158","author":"Ma","year":"2017","journal-title":"Endocrinology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1210\/jc.2015-3709","article-title":"Cord blood ferritin and fibroblast growth factor-23 levels in neonates","volume":"101","author":"Ali","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bone.2010.05.024","article-title":"Fibroblast growth factor 23 concentrations in healthy term infants during the early postpartum period","volume":"47","author":"Takaiwa","year":"2010","journal-title":"Bone"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1210\/jc.2010-2357","article-title":"Circulating levels of soluble alpha-Klotho are markedly elevated in human umbilical cord blood","volume":"96","author":"Ohata","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/1066896912444925","article-title":"Tumoral calcinosis\u2013a pathogenetic overview: A histological and ultrastructural study with a report of two new cases, one in infancy","volume":"20","author":"Slavin","year":"2012","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00402-004-0715-0","article-title":"A case of familial tumoral calcinosis in a neonate and review of the literature","volume":"124","author":"Polykandriotis","year":"2004","journal-title":"Arch. Orthop. Trauma Surg."},{"key":"ref_32","first-page":"70","article-title":"Early biochemical findings in familial hypophosphataemic, hyper- phosphaturic rickets and response to treatment","volume":"7","author":"Moncrieff","year":"1982","journal-title":"Arch. Dis. Child."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.matbio.2004.09.007","article-title":"Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice","volume":"23","author":"Sitara","year":"2004","journal-title":"Matrix Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1210\/en.2013-2061","article-title":"Neither absence nor excess of FGF23 disturbs murine fetal-placental phosphorus homeostasis or prenatal skeletal development and mineralization","volume":"155","author":"Ma","year":"2014","journal-title":"Endocrinology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000443988","article-title":"Fibroblast growth factor 23 concentrations reflect sex differences in mineral metabolism and growth in early infancy","volume":"85","author":"Viljakainen","year":"2016","journal-title":"Horm. Res. Paediatr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/20469047.2016.1248170","article-title":"Nutritional rickets around the world: An update","volume":"37","author":"Creo","year":"2017","journal-title":"Paediatr. Int. Child. Health"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"356","DOI":"10.4103\/ijmr.IJMR_1961_19","article-title":"Nutritional rickets osteomalacia: A practical approach to management","volume":"152","author":"Uday","year":"2020","journal-title":"Indian J. Med. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jsbmb.2013.09.012","article-title":"Vitamin D and DBP: The free hormone hypothesis revisited","volume":"144","author":"Chun","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mantec\u00f3n, L., Alonso, M.A., Moya, V., Andr\u00e9s, A.G., Avello, N., Mart\u00ednez-Morillo, E., and Santos, F. (2018). Marker of vitamin D status in healthy children: Free or total 25-hydroxyvitamin D?. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202237"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/s41430-020-0558-y","article-title":"Vitamin D deficiency 2.0: An update on the current status worldwide","volume":"74","author":"Amrein","year":"2020","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society Clinical Practice Guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000443136","article-title":"Global consensus recommendations on prevention and management of nutritional rickets","volume":"85","author":"Munns","year":"2016","journal-title":"Horm. Res. Paediatr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"17101","DOI":"10.1038\/nrdp.2017.101","article-title":"Rickets","volume":"3","author":"Carpenter","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11914-017-0383-y","article-title":"Nutritional rickets and osteomalacia in the twenty first Century: Revised concepts, public health, and prevention strategies","volume":"15","author":"Uday","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/adc.2003.031385","article-title":"Presentation of vitamin D deficiency","volume":"89","author":"Ladhani","year":"2004","journal-title":"Arch. Dis. Child."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1210\/jc.2014-2773","article-title":"Incidence of hypocalcemic seizures due to vitamin D deficiency in children in the United Kingdom and Ireland","volume":"100","author":"Basatemur","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11914-011-0081-0","article-title":"Rickets","volume":"9","author":"Mughal","year":"2011","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_48","first-page":"CD012581","article-title":"Vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children","volume":"4","author":"Chibuzor","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000357142","article-title":"Serum fibroblast growth factor 23 is a useful marker to distinguish vitamin D-deficient rickets from hypophosphatemic rickets","volume":"81","author":"Kubota","year":"2014","journal-title":"Horm. Res. Paediatr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41390-019-0289-8","article-title":"Vitamin D deficiency in children: A challenging diagnosis!","volume":"85","author":"Alonso","year":"2019","journal-title":"Pediatr. Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Pilz, S., Trummer, C., Theiler-Schwetz, V., Gr\u00fcbler, M.R., Verheyen, N.D., Odler, B., Karras, S.N., Zittermann, A., and M\u00e4rz, W. (2022). Critical appraisal of large vitamin D randomized controlled trials. Nutrients, 14.","DOI":"10.3390\/nu14020303"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jamacardio.2019.1870","article-title":"Vitamin D supplementation and cardiovascular disease risks in more than 83 000 Individuals in 21 randomized clinical trials: A meta-analysis","volume":"4","author":"Barbarawi","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1809944","article-title":"Vitamin D supplements and prevention of cancer and cardiovascular disease","volume":"380","author":"Manson","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"l4673","DOI":"10.1136\/bmj.l4673","article-title":"Association between vitamin D supplementation and mortality, systematic review and meta-analysis","volume":"366","author":"Zhang","year":"2019","journal-title":"BMJ"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.amjms.2019.04.020","article-title":"Efficacy and safety of vitamin D supplementation in patients with systemic lupus erythematosus, A meta-analysis of randomized controlled trials","volume":"358","author":"Zheng","year":"2019","journal-title":"Am. J. Med. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1900906","article-title":"Vitamin D supplementation and prevention of type 2 diabetes","volume":"381","author":"Pittas","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/ibd\/izy346","article-title":"Randomized trial of vitamin D supplementation to prevent seasonal influenza and upper respiratory infection in patients with inflammatory bowel disease","volume":"25","author":"Arihiro","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1001\/jama.2019.17380","article-title":"Effect of vitamin D and omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes, A randomized clinical trial","volume":"322","author":"Zelnick","year":"2019","journal-title":"JAMA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1056\/NEJMoa1915176","article-title":"Vitamin D supplements for prevention of tuberculosis infection and disease","volume":"383","author":"Ganmaa","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"102189","DOI":"10.1016\/j.dsx.2021.102189","article-title":"Vitamin D supplementation and COVID-19 treatment, A systematic review and meta-analysis","volume":"15","author":"Rawat","year":"2021","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"154753","DOI":"10.1016\/j.metabol.2021.154753","article-title":"The link between COVID-19 and vItamin D (VIVID), A systematic review and meta-analysis","volume":"119","author":"Bassatne","year":"2021","journal-title":"Metabolism"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S2213-8587(21)00051-6","article-title":"Vitamin D supplementation to prevent acute respiratory infections, a systematic review and meta-analysis of aggregate data from randomised controlled trials","volume":"9","author":"Jolliffe","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"111024","DOI":"10.1016\/j.nut.2020.111024","article-title":"Effectiveness of oral vitamin D supplementation in lessening disease severity among patients with psoriasis, A systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Theodoridis","year":"2021","journal-title":"Nutrition"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jcf.2020.12.008","article-title":"Vitamin D supplementation in patients with cystic fibrosis, A systematic review and meta-analysis","volume":"20","author":"Varannai","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e066452","DOI":"10.1136\/bmj-2021-066452","article-title":"Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease, VITAL randomized controlled trial","volume":"376","author":"Hahn","year":"2022","journal-title":"BMJ"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/CM9.0000000000001951","article-title":"Vitamin D supplementation in pregnant women or infants for preventing allergic diseases, a systematic review and meta-analysis of randomized controlled trials","volume":"135","author":"Luo","year":"2022","journal-title":"Chin. Med. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3389\/fendo.2018.00320","article-title":"Role of fibroblast growth factor-23 in innate immune responses","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/1873-3468.12096","article-title":"Fibroblast growth factor (Fgf) 23 gene transcription depends on actin cytoskeleton reorganization","volume":"590","author":"Fajol","year":"2016","journal-title":"FEBS Lett."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00109-015-1370-3","article-title":"NFkBsensitive Orai1 expression in the regulation of FGF23 release","volume":"94","author":"Zhang","year":"2016","journal-title":"J. Mol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Real, J.M., Puig, J., Serrano, M., Sabater, M., Rubi\u00f3, A., Moreno-Navarrete, J.M., Fontan, M., Casamitjana, R., Xifra, G., and Ortega, F.J. (2013). Iron and obesity status-associated insulin resistance influence circulating fibroblast- growth factor-23 concentrations. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058961"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1515\/jpem-2012-0064","article-title":"The association of FGF23 levels in obese adolescents with insulin sensitivity","volume":"25","author":"Wojcik","year":"2012","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Tu\u00f1\u00f3n, J., Crist\u00f3bal, C., Tar\u00edn, N., Ace\u00f1a, \u00c1., Gonz\u00e1lez-Casaus, M.L., Huelmos, A., Alonso, J., Lorenzo, \u00d3., Gonz\u00e1lez-Parra, E., and Mah\u00edllo-Fern\u00e1ndez, I. (2014). Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095402"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/CIRCHEARTFAILURE.112.000105","article-title":"FGF23 modifies the relationship between vitamin D and cardiac remodeling","volume":"6","author":"Ky","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40618-017-0739-2","article-title":"Effect of cholecalciferol therapy on serum FGF23 in vitamin D deficient patients, a randomized clinical trial","volume":"41","author":"Kamelian","year":"2018","journal-title":"J. Endocrinol. Investig."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s00198-019-05102-7","article-title":"Oral vitamin D3 supplementation increases serum fibroblast growth factor 23 concentration in vitamin D-deficient patients, a systematic review and meta-analysis","volume":"30","author":"Charoenngam","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00394-018-1672-7","article-title":"Effects of vitamin D supplementation on FGF23, a randomized-controlled trial","volume":"58","author":"Trummer","year":"2019","journal-title":"Eur. J. Nutr."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Bhagatwala, J., Zhu, H., Parikh, S.J., Guo, D.H., Kotak, I., Huang, Y., Havens, R., Pham, M., Afari, E., and Kim, S. (2015). Dose and time responses of vitamin D biomarkers to monthly vitamin D3 supplementation in overweight\/ obese African Americans with suboptimal vitamin d status, a placebo controlled randomized clinical trial. BMC Obes., 2.","DOI":"10.1186\/s40608-015-0056-2"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00467-018-4160-7","article-title":"Growth plate alterations in chronic kidney disease","volume":"35","author":"Santos","year":"2020","journal-title":"Pediatr. Nephrol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00223-020-00787-z","article-title":"Bone disease in CKD in children","volume":"108","author":"Santos","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update, what\u2032s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrneph.2011.137","article-title":"Nutrition and growth in children with chronic kidney disease","volume":"7","author":"Rees","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1210\/jc.2008-0326","article-title":"Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis","volume":"94","author":"Pereira","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/jc.2009-1576","article-title":"The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease","volume":"95","author":"Bacchetta","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1210\/jc.2009-1603","article-title":"Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active","volume":"95","author":"Shimada","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2215\/CJN.05940611","article-title":"Early skeletal and biochemical alterations in pediatric chronic kidney disease","volume":"7","author":"Pereira","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/00365510903359245","article-title":"A prospective study of fibroblast growth factor-23 in children with chronic kidney disease","volume":"70","author":"Magnusson","year":"2010","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ndt\/gfs411","article-title":"Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease","volume":"28","author":"Wan","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2215\/CJN.05840513","article-title":"Disordered FGF23 and mineral metabolism in children with CKD","volume":"9","author":"Portale","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1681\/ASN.2014090947","article-title":"Normal 25-hydroxyvitamin D levels are associated with less proteinuria and attenuate renal failure progression in children with CKD","volume":"27","author":"Shroff","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Yasin, A., Liu, D., Chau, L., Madrenas, J., and Filler, G. (2013). Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients, a cross-sectional study. BMC Nephrol., 14.","DOI":"10.1186\/1471-2369-14-39"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ckj\/sfu074","article-title":"Longitudinal FGF23 and Klotho axis characterization in children treated with chronic peritoneal dialysis","volume":"7","author":"Cano","year":"2014","journal-title":"Clin. Kidney J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2215\/CJN.02110216","article-title":"Fibroblast growth factor 23 and risk of CKD progression in children","volume":"11","author":"Portale","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00467-015-3190-7","article-title":"Prevalence and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children (CKiD) cohort","volume":"31","author":"Kumar","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Liu, D., Alvarez-El\u00edas, A.C., Wile, B., Belostotsky, V., and Filler, G. (2017). Deviations from the expected relationship between serum FGF23 and other markers in children with CKD, a cross-sectional study. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0623-5"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/ndt\/gfy012","article-title":"Effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease","volume":"33","author":"Lerch","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00431-019-03553-y","article-title":"Intermittent cholecalciferol supplementation in children and teenagers followed in pediatric nephrology, data from a prospective single-center single-arm open trial","volume":"179","author":"Aurelle","year":"2020","journal-title":"Eur. J. Pediatr."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s12098-022-04247-4","article-title":"Short-term effects of cholecalciferol supplementation on cFGF23 levels in children with chronic kidney disease and vitamin D Insufficiency","volume":"89","author":"Sheriff","year":"2022","journal-title":"Indian J. Pediatr."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.bone.2009.08.008","article-title":"Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease","volume":"45","author":"Pereira","year":"2009","journal-title":"Bone"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1093\/ndt\/gfs109","article-title":"Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD Stages 3\u20135","volume":"27","author":"Sinha","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1681\/ASN.2014010104","article-title":"Proteinuria increases plasma phosphate by altering its tubular handling","volume":"26","author":"Courbebaisse","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1399-3046.2011.01613.x","article-title":"Are fibroblast growth factor 23 concentrations in renal transplant patients different from non-transplanted chronic kidney disease patients?","volume":"16","author":"Filler","year":"2012","journal-title":"Pediatr. Transplant."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s00467-020-04843-6","article-title":"Fibroblast growth factor 23-Klotho and hypertension, experimental and clinical mechanisms","volume":"36","author":"Freundlich","year":"2021","journal-title":"Pediatr. Nephrol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00467-012-2224-7","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis","volume":"27","author":"Seeherunvong","year":"2012","journal-title":"Pediatr. Nephrol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/ndt\/gfv421","article-title":"Induction of cardiac FGF23\/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease","volume":"31","author":"Flasbart","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s00467-015-3125-3","article-title":"Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease","volume":"30","author":"Sinha","year":"2015","journal-title":"Pediatr. Nephrol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2215\/CJN.02110217","article-title":"FGF23 and left ventricular hypertrophy in children with CKD","volume":"13","author":"Mitsnefes","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1681\/ASN.2017121334","article-title":"Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases, a meta-analysis","volume":"29","author":"Marthi","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/petr.12682","article-title":"Fibroblast growth factor-23 and chronic allograft injury in pediatric renal transplant recipients, a Midwest Pediatric Nephrology Consortium study","volume":"20","author":"Seifert","year":"2016","journal-title":"Pediatr. Transplant."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1093\/ndt\/gfr126","article-title":"Mineral abnormalities and long-term graft function in pediatric renal transplant recipients, a role for FGF-23?","volume":"26","author":"Tsai","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00467-012-2110-3","article-title":"Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function","volume":"27","author":"Bacchetta","year":"2012","journal-title":"Pediatr. Nephrol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"8349","DOI":"10.1096\/fj.201802007R","article-title":"MAPK inhibition and growth hormone, a promising therapy in XLH","volume":"33","author":"Fuente","year":"2019","journal-title":"FASEB J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.pcl.2018.09.004","article-title":"Hypophosphatemic rickets","volume":"66","author":"Bitzan","year":"2019","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00467-021-05328-w","article-title":"Rickets guidance, part I-diagnostic workup","volume":"37","author":"Haffner","year":"2022","journal-title":"Pediatr. Nephrol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00774-009-0079-1","article-title":"Hypophosphatemia, the common denominator of all rickets","volume":"27","author":"Tiosano","year":"2009","journal-title":"J. Bone Miner. Metab."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eprac.2022.09.007","article-title":"Phosphatonins, from discovery to therapeutics","volume":"29","author":"Kritmetapak","year":"2023","journal-title":"Endocr. Pract."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00424-018-2184-2","article-title":"Hereditary hypophosphatemic rickets with hypercalciuria, pathophysiology, clinical presentation, diagnosis and therapy","volume":"471","author":"Bergwitz","year":"2019","journal-title":"Pflugers Arch."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00467-020-04906-8","article-title":"Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia","volume":"36","author":"Giralt","year":"2021","journal-title":"Pediatr. Nephrol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00223-022-01005-8","article-title":"Tumor-induced osteomalacia, a systematic clinical review of 895 cases","volume":"111","author":"Bosman","year":"2022","journal-title":"Calcif. Tissue Int."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","article-title":"Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients, Proposal of diagnostic criteria using FGF23 measurement","volume":"42","author":"Endo","year":"2008","journal-title":"Bone"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/jbmr.4702","article-title":"Determination of FGF23 levels for the diagnosis of FGF23-mediated hypophosphatemia","volume":"37","author":"Hartley","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000346786","article-title":"Vitamin D and type II sodium-dependent phosphate cotransporters","volume":"180","author":"Kido","year":"2013","journal-title":"Contrib. Nephrol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"153865","DOI":"10.1016\/j.metabol.2019.01.006","article-title":"Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting","volume":"103S","author":"Bacchetta","year":"2020","journal-title":"Metabolism"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Mughal","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12325-019-01178-z","article-title":"X-linked hypophosphataemic rickets and growth","volume":"37","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1359\/jbmr.060507","article-title":"Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women","volume":"21","author":"Burnett","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1381e8","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.2009-1671","article-title":"Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations","volume":"95","author":"Imel","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1210\/jc.2010-0589","article-title":"Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia, circadian variance, effects of treatment, and relationship to parathyroid status","volume":"95","author":"Carpenter","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13023-021-01729-0","article-title":"Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population","volume":"16","author":"Chocron","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1210\/jc.2014-2017","article-title":"Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia, a randomized, double-blind, placebo-controlled study","volume":"99","author":"Carpenter","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2215\/CJN.04981107","article-title":"Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets","volume":"3","author":"Alon","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia, a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia, a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fped.2020.00048","article-title":"Positive response to one-year treatment with burosumab in pediatric patients with X-linked hypophosphatemia","volume":"8","author":"Santos","year":"2020","journal-title":"Front. Pediatr."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/jbmr.3992","article-title":"Hyperparathyroidism in patients with X-linked hypophosphatemia","volume":"35","author":"Lecoq","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia, week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1359\/jbmr.070107","article-title":"FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets","volume":"22","author":"Imel","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1210\/jc.2011-1239","article-title":"Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans","volume":"96","author":"Imel","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/jbmr.3878","article-title":"Oral iron replacement normalizes fibroblast growth factor 23 in iron-deficient patients with autosomal dominant hypophosphatemic rickets","volume":"35","author":"Imel","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/clinem\/dgac433","article-title":"Burosumab treatment for autosomal recessive hypophosphatemic rickets type 1 (ARHR1)","volume":"107","author":"Bai","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00774-004-0589-9","article-title":"The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome","volume":"23","author":"Yamamoto","year":"2005","journal-title":"J. Bone Miner. Metab."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/jbmr.3649","article-title":"Age-related changes and effects of bisphosphonates on bone turnover and disease progression in fibrous dysplasia of one","volume":"34","author":"Florenzano","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"116004","DOI":"10.1016\/j.bone.2021.116004","article-title":"Burosumab treatment for fibrous dysplasia","volume":"150","author":"Gladding","year":"2021","journal-title":"Bone"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Apperley, L.J., and Senniappan, S. (2022). Burosumab therapy in a paediatric patient with McCune-Albright Syndrome: A case report. Horm. Res. Paediatr.","DOI":"10.1159\/000527129"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"101138","DOI":"10.1016\/j.bonr.2021.101138","article-title":"Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report","volume":"15","author":"Khadora","year":"2021","journal-title":"Bone Rep."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"86683","DOI":"10.3389\/fendo.2022.866831","article-title":"A case report: First long-term treatment with burosumab in a patient with cutaneous-skeletal hypophosphatemia syndrome","volume":"13","author":"Merz","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jbmr.4184","article-title":"Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia","volume":"36","author":"Imanishi","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Miller","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-2008-1076716","article-title":"Hypophosphatemic rickets with hypercalciuria due to mutation in SLC34A3\/NaPi-IIc can be masked by vitamin D deficiency and can be associated with renal calcifications","volume":"117","author":"Kremke","year":"2009","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.bone.2012.02.015","article-title":"Novel NaPi-IIc mutations causing HHRH and idiopathic hypercalciuria in several unrelated families, long-term follow-up in one kindred","volume":"50","author":"Yu","year":"2012","journal-title":"Bone"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1681\/ASN.2014101025","article-title":"Autosomal-recessive mutations in SLC34A1 encoding sodium-phosphate cotransporter 2A cause idiopathic infantile hypercalcemia","volume":"27","author":"Schlingmann","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1210\/clinem\/dgaa217","article-title":"Digenic heterozygous mutations in SLC34A3 and SLC34A1 cause dominant hypophosphatemic rickets with hypercalciuria","volume":"105","author":"Gordon","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"752312","DOI":"10.3389\/fped.2021.752312","article-title":"Childhood hypercalciuric hypercalcemia with elevated vitamin D and suppressed parathyroid hormone, long-term follow up","volume":"9","author":"Gurevich","year":"2021","journal-title":"Front. Pediatr."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000520299","article-title":"Variable clinical presentation of children with hereditary hypophosphatemic rickets with hypercalciuria, a case series and review of the literature","volume":"94","author":"Christensen","year":"2021","journal-title":"Horm. Res. Paediatr."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"736240","DOI":"10.3389\/fendo.2021.736240","article-title":"Overlapping phenotypes associated with CYP24A1, SLC34A1, and SLC34A3 mutations, a cohort study of patients with hypersensitivity to vitamin D","volume":"12","author":"Molin","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1056\/NEJMoa0905647","article-title":"A loss-of-function mutation in NaPi-IIa and renal Fanconi\u2032s syndrome","volume":"362","author":"Magen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/klotho endocrine pathways","volume":"92","author":"Martin","year":"2012","journal-title":"Physiol. Rev."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bone.2016.09.010","article-title":"FGF23-klotho signaling axis in the kidney","volume":"100","author":"Erben","year":"2017","journal-title":"Bone"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jmgm.2017.04.024","article-title":"Targeted inhibition of klotho binding to fibroblast growth factor 23 prevents hypophosphatemia","volume":"75","author":"Fakhar","year":"2017","journal-title":"J. Mol. Graph. Model."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6661\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:08:54Z","timestamp":1760123334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":163,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24076661"],"URL":"https:\/\/doi.org\/10.3390\/ijms24076661","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]}}}